How GLP 1 therapy affects fasting insulin levels
Glucagon-like peptide 1 (GLP-1) is a hormone that plays a crucial role in regulating blood sugar levels. GLP-1 therapy, which involves the administration of GLP-1 receptor agonists, has been shown to have a significant impact on fasting insulin levels. In this article, we will explore the effects of GLP-1 therapy on fasting insulin levels and what this means for individuals with diabetes and other metabolic disorders.
The Incretin Effect and GLP-1
GLP-1 is an incretin hormone that is released from the intestinal L-cells in response to food intake. It enhances insulin secretion and suppresses glucagon release, thereby helping to lower blood sugar levels. The incretin effect is a physiological phenomenon that describes the observation that oral glucose administration elicits a much higher insulin response than an isoglycemic intravenous (IV) glucose infusion.
How GLP-1 Receptor Agonists Affect Fasting Plasma Glucose Levels
One of the primary benefits of GLP-1 receptor agonists is their ability to lower fasting plasma glucose levels. Fasting plasma glucose refers to the amount of glucose present in the bloodstream after an overnight fast. By stimulating insulin secretion and suppressing glucagon release, GLP-1 receptor agonists help reduce the levels of glucose in the blood.
